Purpose: To investigate the effects of ursolic acid (UA) on expressions of ERK1, C-Jun, C-Myc and Cyclin D1 in Human Umbilical Vein Endothelial Cells (HUVEC), and to explore the mechanism of anticancer activity of UA on glioma. Methods: HUVEC was treated with UA (0, 31.5, 62.5, 125, 250, 500 μg/mL) for 24 h, and 125 μg/mL for 0, 12, 24, 48 h, respectively) and PD98059 in vitro. Real-time polymerase chain reaction (RT-PCR) was performed to measure the endogenous mRNA levels of ERK1, C-Jun, C-Myc, and Cyclin D1, and Western blotting was used to determine the expressions of ERK1, C-Jun, C-Myc, and Cyclin D1 proteins.
INTRODUCTION
Ursolic acid (UA) is a pentacyclic triterpenoid isolated from Chinese herbal medicine and exists widely in Bearberry, Ligustrum lucidum. Pharmacological studies indicate that it has many biological effects [1] . Recent investigations suggest that UA not only has wide resistance to the effects of carcinogens, but also inhibits endothelial cell proliferation [2] and tumor formation [3] . It has drawn increasing interest as one of the most promising cancer chemopreventive drugs in the world; however, the mechanism of its action is still unclear. Recently, it was reported that UA functions as an anti-proliferation agent of U87 glioma cells [4] .
The malignant proliferation of C6 glioma cells can be inhibited by inhibiting the activity of ERK signaling pathway [5] . Furthermore, it has also been confirmed that VEGF can promote endothelial cell mitosis by activation of ERK signaling pathway. From results of the previous investigations, we believe that UA may inhibit the proliferation of astrocyte tumor vascular endothelial cells by inhibiting ERK signaling pathway, thereby inhibiting the growth of glioma.
In the present study, the effects of UA on ERK1, C-Jun, C-Myc, Cyclin D1 expressions in HUVEC were investigated with malignant glioma vascular endothelial cells by using RT-PCR and Western blot. The present investigation is designed to study the molecular mechanisms by which UA inhibits tumor cell proliferation, as well as develop a new biological target and new ideas in glioma biological treatment. 
RT-PCR examination and ERK1, C-Myc, C-Jun and Cyclin D1 mRNA expression
Cells were harvested, and the total RNA was extracted according to BIOZOL reagent instruction manual. Total RNA was used for cDNA synthesis by reverse transcription, and cDNA of ERK1, C-Myc, C-Jun, Cyclin D1 and β-actin were amplified by PCR. All mRNA primers were designed by Primer Premier 5.0 and synthesised by SBS Genetech Co, Ltd. The primers used for the PCR are in Table 1 . PCR was performed according to the manufacturer's instructions of RT-PCR reaction kit (TaKaRa, Japan). Amplification products were analyzed on 1.0 % agarose gel electrophoresis and computer image analysis meter. Agarose gel electrophoresis was undertaken to analyze the PCR products and their photos collected. Electrophoresis band intensities of ERK1, C-Myc, C-Jun, CyclinD1 mRNA/β-actin were determined by imaging analysis system and statistical analysis software and the optical density (OD) of ERK1, C-Myc,C-Jun ,Cyclin D1 mRNA/β-actin calculated.
Expressions of ERK1, C-Myc, C-Jun and CyclinD1 proteins
Cells were harvested, and the total protein was extracted. Then, equal amounts of protein (40 μg) were separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE), blotted on polyvinylidene difluoride (PVDF), and probed with rabbit anti-human ERK1 or C-Myc or C-Jun or Cyclin D1 polyclonal anti-body, and subsequently with goat antirabbit/HRP, and detected by chemiluminescence. To measure protein loading, antibodies directed against β-actin were used. Comparison and analysis of area and gray intensity of electrophoresis bands were performed by the Quantity one 1D gel analysis software (version 4.6.2, Bio-Rad). 
Statistical analysis
All of the data are presented as mean ±SD, and were evaluated with one-way ANOVA followed by Dunnett multiple comparisons post-test between different groups. Statistical analysis was carried out using SPSS software (SPSS for Windows, version 15.0, SPSS Inc, USA) with the level of significance set p < 0.05.
RESULTS mRNA expression of ERK1, C-Myc,CJun,Cyclin D1
The results show that expression of ERK1,CMyc,C-Jun,CyclinD1 mRNA of HUVEC in group 1(treated with 125μg/ml UA) and group 2(treated with PD98059 100μmol/L) were significantly lower than one of blank control group (p < 0.05), as Figure 1 indicates. After HUVEC were treated with different UA doses (0, 31.5, 62.5, 125, 250, 500 μg/mL), the expression of ERK1, C-Myc, C-Jun, Cyclin D1 mRNA decreased with UA dosage increase and then the expression of ERK1, C-Myc, C-Jun, CyclinD1 mRNA were significantly different beginning from 125μg/ml UA dosage between groups treated with different dosage and control group, among groups treated with different dosage. The differences were statistically significant (p < 0.05), as shown in Figure 2 . Further, after HUVEC were treated with 125μg/ml UA dosage, the PCR results showed that the expressions of ERK1, C-Myc, C-Jun, Cyclin D1 mRNA decreased with time and then the expression of ERK1, C-Myc, C-Jun, CyclinD1 mRNA were significantly different beginning from the 12th hour between different time groups and control group ,among different time groups (Figure 3 ). The differences are statistically significant (p < 0.05).
Expressions of ERK1, C-Myc, C-Jun, and Cyclin D1
Western blot results were obtained from image analysis (Figure 4) . The results indicate that expression of ERK1, C-Myc, C-Jun, CyclinD1 of HUVEC in UA and PD98059 groups were significantly lower than that of control (p < 0.05).
After HUVEC were treated with different UA doses (0, 31.5, 62.5, 125, 250 and 500 μg/mL), the expressions of ERK1, C-Myc, C-Jun, Cyclin D1 decreased with increase in UA ( Figure 5) ; the expressions of ERK1, C-Myc, C-Jun, CyclinD1 mRNA were significantly different at UA doses of 125, 250 and 500 μg/mL (p < 0.05). In addition, following treatment of HUVEC with 125 μg/ml UA, the expression of ERK1, C-Myc, C-Jun, Cyclin D1 mRNA decreased with time ( Figure 6 ); the expression of ERK1, C-Myc,CJun,CyclinD1 were significantly different in the groups of 12, 24 and 48 h (p < 0.05). 
DISCUSSION
Chinese herbal medicines have been used in China for treatment of a wide variety of diseases with low adverse effects [6, 7] . UA is an α-amyrin-type pentacyclic triterpenoid, and has wide biology effects, including inhibition of growth of various malignant cells [1] . Currently, its anticancer effect is attracting considerable attention from pharmacologists. Angiogenesis is the key pathological process of tumor development and metastasis [8] . In tumor angiogenesis, activation, proliferation, migration and canaliculization of vascular endothelia cells (VEC) are important steps. Now many angiogenesis inhibitors, such as trotamine, interferon and platelet factor IV have been found but their clinical applications have been restricted because of high toxicity. As a potent new anti-tumor natural drug with high anti-tumor effect and low toxicity, UA has vast potential as a new drug for cancer treatment [9] .
Wang et al [10] suggested that UA has the ability to inhibit angiopoiesis of proliferative phase VEC in-vitro in a dose-dependent manner. Sohn et al [11] also obtained similar results using chorioallantoic membranes (CAM) of chicken embryo model. However, the mechanism of UA action is not yet clear. In our present study, we focused on the mechanism of inhibition of VEC proliferation by UA. PD98059 is a powerful ERK inhibitor which can selectively inhibit ERK activity so as to inhibit the proliferation of malignant glioma cells C6, thereby inducing their differentiation. The RT-PCR results of our present study show that expressions of ERK1, CMyc, C-Jun, CyclinD1 mRNA of HUVEC in UA group and PD98059 group were significantly lower than that of blank control group (p < 0.05) This indicates that both UA and PD98059 can inhibit the ERK signal pathway of HUVEC. Western blot results revealed that expressions of ERK1, C-Myc, C-Jun, CyclinD1 of HUVEC in UA group and PD98059 group were significantly lower than that of blank control group (p<0.05), and the results further demonstrate that UA can inhibit the ERK signal pathway of HUVEC, just like PD98059 effect, which is consistent with some literature reports 12,13]. Huang et al [14] suggested that the inhibition of ERK1/2 signal pathway may block VEC proliferation in their research on effects of tumstatin peptide on retinal microvascular endothelial cell (RMEC) proliferation. Therefore, we presume that UA and PD98059 can inhibit VEC proliferation by inhibiting the ERK signal pathway of HUVEC. Our results also show that the expressions of ERK1, C-Myc, C-Jun, Cyclin D1 mRNA and protein decreased gradually with UA dose and time and were significantly different between different dosage and time groups (p < 0.05). This shows that the inhibition of the ERK signal pathway of HUVEC by UA is dose-and timedependent.
CONCLUSION
The findings of the present study indicate that the UA can significantly inhibit the generation of vascular endothelial cells of glioma by downregulating the expressions of ERK1, C-Jun, CMyc and Cyclin D1 of ERK signal transduction pathway, which is of potential value for the treatment of vascular endothelial glioaytoma.
